Experimental immunotherapy shows high response rate in advanced lung cancer
Friday, May 15, 2015 - 13:30
in Health & Medicine
An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer.